Leap Investments’s Spyre Therapeutics SYRE Stock Holding History

Leap Investments’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-664	Closed	-$114K	–	486
2019 Q2	$114K	Buy	+664	New	+$115K	0.15%	199

Other funds holding SYRE

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Leap Investments's SYRE Position: Q3 2019 in Review

Leap Investments sold out of Spyre Therapeutics (SYRE) in Q3 2019, closing a stake of 664 shares — an estimated $114K sold.

Leap Investments first reported a position in SYRE in Q2 2019 and held it in 1 quarter. The position peaked at $114K in Q2 2019. 71 funds tracked by Wall St. Rank hold SYRE as of Q3 2019.

Leap Investments reported no remaining Spyre Therapeutics position as of Q3 2019 after selling out during the quarter.
Leap Investments sold 664 Spyre Therapeutics shares in Q3 2019, an estimated $114K.
Leap Investments first reported a position in Spyre Therapeutics in Q2 2019 and held it in 1 quarter.
Leap Investments's Spyre Therapeutics position peaked at $114K in Q2 2019.
71 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2019.

Based on Leap Investments's 13F filing for Q3 2019, filed 13 Nov 2019.